BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32443875)

  • 1. In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against
    Nguyen LP; Pinto NA; Vu TN; Lee H; Cho YL; Byun JH; D'Souza R; Yong D
    Antibiotics (Basel); 2020 May; 9(5):. PubMed ID: 32443875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant
    Nguyen LP; Park CS; Pinto NA; Lee H; Seo HS; Vu TN; Mai H; Pham AHT; Jang E; Cho YL; Goglin K; Nguyen K; White R; D'Souza R; Fouts DE; Yong D
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33923801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES; Sanders CC; Thomson KS
    J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.
    Stürenburg E; Lang M; Horstkotte MA; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Nov; 54(5):870-5. PubMed ID: 15471997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
    Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
    Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).
    Sader HS; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Feb; 69(2):223-7. PubMed ID: 21251571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
    Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
    Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial Activity of LCB10-0200 against
    Oh SH; Kim YR; Park HS; Oh KM; Cho YL; Kwak JH
    Antibiotics (Basel); 2021 Sep; 10(10):. PubMed ID: 34680766
    [No Abstract]   [Full Text] [Related]  

  • 15. AmpC beta-lactamase producing multidrug resistant strains of Klebsiella spp. & Escherichia coli isolated from children under five in Chennai.
    Subha A; Devi VR; Ananthan S
    Indian J Med Res; 2003 Jan; 117():13-8. PubMed ID: 12866821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nosocomial blood-stream infections from extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumonia from GB Pant Hospital, New Delhi.
    Taneja J; Mishra B; Thakur A; Dogra V; Loomba P
    J Infect Dev Ctries; 2010 Sep; 4(8):517-20. PubMed ID: 20818104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.
    Kohler J; Dorso KL; Young K; Hammond GG; Rosen H; Kropp H; Silver LL
    Antimicrob Agents Chemother; 1999 May; 43(5):1170-6. PubMed ID: 10223931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
    Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
    Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftiofur tested against clinical isolates of Escherichia coli and Klebsiella pneumoniae including extended spectrum beta-lactamase producing strains.
    Deshpande L; Pfaller MA; Jones RN
    Int J Antimicrob Agents; 2000 Aug; 15(4):271-5. PubMed ID: 10929876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.